Case of peripartum cardiomyopathy misdiagnosed as pulmonary changes due to COVID-19
D. V. Gavrilov,
Z. R. Bagirova,
D. I. Pleskatsevich,
O. V. Kuznetsova,
A. A. Ivshin,
T. Yu. Kuznetsova https://doi.org/10.18087/cardio.2022.12.n1668
Abstract
A 37-year-old female patient was admitted 16 days after delivery in a hospital for infectious diseases with cough, shortness of breath, and infiltrative changes in the lungs that were interpreted as viral pneumonia. Considering the failure of therapy and the history, peripartum cardiomyopathy was suspected. Examination revealed a decrease in left ventricular ejection fraction to 30 %, ultrasonic signs of lung congestion and bilateral hydrothorax. The patient was diagnosed with peripartum cardiomyopathy accompanied by functional class 4 heart failure. A specific feature of this case was fast positive dynamics with complete regression of the clinical picture of congestion and improvement of the left ventricular myocardial function associated with the treatment.
Supporting agencies: No conflict of interest is reported.
About the Authors
D. V. Gavrilov
ООО “K-Skay”
Russian Federation
Russian Federation
Chief Medical Officer
Petrozavodsk, Russia
Z. R. Bagirova
Emergency Care Hospital
Russian Federation
Russian Federation
Cardiologist, Cardiology Department
Petrozavodsk, Russia
D. I. Pleskatsevich
Emergency Care Hospital
Russian Federation
Russian Federation
Cardiologist, Cardiology Department
Petrozavodsk, Russia
O. V. Kuznetsova
Emergency Care Hospital
Russian Federation
Russian Federation
Head of the Functional Diagnostics Department
Petrozavodsk, Russia
A. A. Ivshin
Petrozavodsk State Medical University
Russian Federation
Russian Federation
Ph.D., Head of the Department of Obstetrics and Gynecology, Dermatovenerology
Petrozavodsk, Russia
T. Yu. Kuznetsova
Petrozavodsk State Medical University
Russian Federation
Russian Federation
D.Med.Sc., Head of the Department of Faculty Therapy, Phthisiology, Infectious Diseases and Epidemiology
Petrozavodsk, Russia
References
1. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European Journal of Heart Failure. 2010;12(8):767–78. DOI: 10.1093/ eurjhf/hfq120
2. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A et al. Pregnancy-Associated Cardiomyopathy: Clinical Characteristics and a Comparison Between Early and Late Presentation. Circulation. 2005;111(16):2050–5. DOI: 10.1161/01.CIR.0000162478.36652.7E
3. Pyatt JR, Dubey G. Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments. Postgraduate Medical Journal. 2011;87(1023):34–9. DOI: 10.1136/pgmj.2009.096594
4. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485(7398):333–8. DOI: 10.1038/nature11040
5. Bauersachs J, Konig T, Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure. 2019;21(7):827–43. DOI: 10.1002/ejhf.1493
6. Behrens I, Basit S, Lykke JA, Ranthe MF, Wohlfahrt J, Bundgaard H et al. Hypertensive disorders of pregnancy and peripartum cardiomyopathy: A nationwide cohort study. PLOS ONE. 2019;14(2):e0211857. DOI: 10.1371/journal.pone.0211857
7. Vatutin N.T., Taradin G.G., Popelnukhina L.G., Gritzenko Yu.P., Sidorenko I.A. Treatment of peripartum cardiomyopathy (review). Archive of internal medicine. 2017;7(5):340–9. DOI: 10.20514/2226-6704-2017-7-5-340-349
8. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K et al. A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy. Cell. 2007;128(3):589–600. DOI: 10.1016/j.cell.2006.12.036
9. Kurbanov R.D., Mirzarakhimova S.T., Abdullaev T.A., Tsoy I.A. The Effect of Bromocriptine on Clinical and Laboratory Parameters in Patients With Peripartum Cardiomyopathy. Kardiologiia. 2020;60(6):58–62. DOI: 10.18087/cardio.2020.6.n984
10. Arany Z, Elkayam U. Peripartum Cardiomyopathy. Circulation. 2016;133(14):1397–409. DOI: 10.1161/CIRCULATIONAHA.115.020491
11. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJS, Crespo-Leiro MG et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure. 2016;18(9):1096–105. DOI: 10.1002/ejhf.586
12. Fett JD, Sannon H, Thelisma E, Sprunger T, Suresh V. Recovery from severe heart failure following peripartum cardiomyopathy. International Journal of Gynecology & Obstetrics. 2009;104(2):125–7. DOI: 10.1016/j.ijgo.2008.09.017
13. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, Bauersachs J. Peripartum cardiomyopathy: current management and future perspectives. European Heart Journal. 2015;36(18):1090–7. DOI: 10.1093/eurheartj/ehv009
Review
For citations:
Gavrilov D.V., Bagirova Z.R., Pleskatsevich D.I., Kuznetsova O.V., Ivshin A.A., Kuznetsova T.Yu. Case of peripartum cardiomyopathy misdiagnosed as pulmonary changes due to COVID-19. Kardiologiia. 2022;62(12):80-84. (In Russ.) https://doi.org/10.18087/cardio.2022.12.n1668
Views:
1256
Email this article 
Post a Comment 
